Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

NCT06408194 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Acute Lymphoblastic Leukemia

Interventions

DRUG: CD22CART infusion
DRUG: Tisagenlecleucel

Sponsor

Stanford University